Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07561125 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from International Peace Maternity and Child Health Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Start date changed from estimate of Apr 2026 to Apr 23, 2026
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: 7 to 8
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
It is intended to examine the short-term and long-term efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms born at 28 weeks and below. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.
Trial Details
NCT Number NCT07561125
Lead Sponsor International Peace Maternity and Child Health Hospital
Conditions
(from sponsor)		 Bronchopulmonary Dysplasia
Related terms Bronchopulmonary Dysplasia
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov